Gopi Suvanam, Founder of InvestWorks told CNBC-TV18, "Ranbaxy Laboratories is quite volatile. Cipla seems attractive at the moment. Even Lupin is attractive but it has run-up quite a bit. Cipla still at Rs 400 levels is looking attractive both from valuations and also from a technical standpoint. So I would build some positions in Cipla."
He further added, "I would start looking at slightly more volatile stocks like Dr Reddys Laboratories to add to the portfolio. Avoid Ranbaxy and Sun Pharma at the moment but look at Lupin, Cipla, Dr Reddys and even Wockhardt purely from a valuation perspective."
On January 14, 2013 Cipla closed at Rs 411, up Rs 8.40, or 2.09 percent.
The share touched its 52-week high Rs 450 and 52-week low Rs 354.40 on 16 September, 2013 and 01 March, 2013, respectively.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
